News

Novo Nordisk downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...
Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...